Workshop

Lipids and Beyond - Innovation in Lipid and LNP development and manufacturing

October 27, 2025​ | Frankfurt, Germany


Overview

Lipids are among the most clinically significant excipients in drug delivery systems, playing a particularly vital role in nucleic acid-based therapies e.g. mRNA vaccines. As a trusted CDMO partner, Evonik brings decades of expertise in both the synthesis of these excipients and the clinical manufacturing of lipid-based drug delivery systems. The workshop will focus on the evolving role of lipids in the drug delivery, with key insights into critical success factors. Beyond scaling challenges of lipid nanoparticles, we will discuss their critical role in enabling RNA-based therapies.

We are delighted to welcome our guest speakers from Ethris GmbH, Knauer GmbH and NovoArc who will present on innovative and exciting delivery technologies.


Key learnings for participants

  • Introducing tools necessary to support successful lipid and LNP development and manufacturing
  • LNP formulations – their up and downscaling
  • Advances in parenteral, pulmonary and oral delivery




Note: Please fill in your details and click 'Submit' to register for the workshop. Once we have received your registration, we will send you a status notification as soon as possible. Due to the high demand for our workshops, we sometimes need to reject registrations or put you on a waiting list. Workshop materials will be available for download at the end of the workshop. Any photographs taken during the event are the property of Evonik and may be used for promotional purposes.


Details
Participation fee: Free of charge 
Workshop language: English



Agenda
The workshop will start at 12:30 p.m. on Monday, October 27, 2025, and finish at 5:30 p.m. on the same day. To see the detailed workshop program please click here.



Venue
The workshop will take place at:
K1 Business Club
Neue Mainzer Str. 52-58,
60311 Frankfurt
Germany


This event will be hosted by Evonik Health Care.

Fill out the form to register for the workshop:

Agenda

12:30 a.m. | Registration, Light Lunch and Networking​

01:30 p.m. | Welcome & Introduction to Evonik Health Care
Dr. Rima Jaber
Global Product Manager, Lipids
Evonik Health Care

01:45 p.m. | Introduction to Lipids and LNPs​
Dr. Rima Jaber
Global Product Manager, Lipids
Evonik Health Care

02:15 p.m. | Stable and Precise mRNA Delivery: Transforming Respiratory Medicine and Beyond​
Dr. Philipp Schreppel
Senior Director Business Development
Ethris GmbH

03:00 p.m. | ​Coffee Break & Networking

03:30 p.m. | Unprecedented Lipids for Improved Drug Delivery
Univ. Prof. Oliver Spadiut
Head of the Research Area Biochemical Engineering
TU Wien, NovoArc

04:15 p.m. | Innovation in Lipid and LNP Development at Evonik
Dr. Sophie Hammer
Technical and Strategic Marketing Manager
Evonik Health Care

05:00 p.m. | Next-Generation LNP Mixing Technologies
Michael Frederik Fuss
Business Development Manager
Knauer GmbH

05:30 p.m. | Wrap Up & Goodbye





​
Disclaimer
Notice for business transactions
We assume that you are not currently or foreseeably involved in a business decision in favour of or in direct connection with the Evonik Group or, if this is the case, the decision will not be influenced by this invitation. Therefore, we do not see any concerns on our part regarding your participation. However, we would like to ask you to ensure that you are allowed to accept the invitation in accordance with the regulations that apply to you.

Note for public officials
We assume that you are not or have not been involved in any official act in favour of or in connection with the Evonik Group, either now or in the foreseeable future or in the past and therefore your participation in the event is not subject to any concerns. In addition, we ask you to ensure that your superior approves your participation or you may also accept the invitation in accordance with the rules applicable to you. By registering or participating, you confirm to us that the acceptance of this invitation is permitted according to your internal rules and that you have obtained all necessary approvals. If this is not the case, we ask you for a corresponding note.

Tax notices
Any tax liability resulting from this event will be borne by Evonik Industries AG through a flat-rate tax levy pursuant to Section 37b of the German Income Tax Act (EStG). If you are not taxable in Germany, please clarify whether you must report the invitation to your employer for taxation or whether taxation must be made via your income tax return.



QUESTIONS? 

George William Smith
Senior Business Manager Parenteral Drug Delivery EMEA
+44 7496 257839

Univ. Prof. Oliver Spadiut

Oliver studied Biotech at BOKU University in Vienna before doing a PostDoc at KTH in Stockholm. Since 2010 he has been employed at TU Wien at the Institute of Chemical, Environmental and Bioscience Engineering. In 2015 he habilitated in the field “Biotechnology” and he has been appointed Full Professor in Biochemical Engineering in 2023. He is leading the research area of Biochemical Engineering at TU Wien and is Co-Founder of the Start-Up NovoArc.

Dr. Sophie Hammer

Sophie is a Senior Manager Strategic & Technical Marketing for LNPs at Evonik and based in Darmstadt, Germany. She is the technical point of contact for prospective clients for LNP-based drugs. In her role she focuses on technical assessments and strategic collaborations to advance the development of innovative mRNA-based medicines. Before joining Evonik in 2023 she worked in a global specialty chemical company and served in key positions such as product expert, project manager and product manager. Sophie studied Biomedical Chemistry at the University of Mainz, Germany, and holds a PhD degree in Polymer Chemistry. She is the author of multiple peer-reviewed publications in the polymer and lipid-based nanoparticle field.

Dr. Rima Jaber

Rima joined Evonik in 2009 and has held multiple R&D roles in Germany and abroad. She has over 10 years’ experience in parenteral and complex oral formulations and the handling of highly potent active pharmaceutical ingredients. In her previous positions, she also gained experience in managing the development of new biomaterials for medical device applications, managing publicly funded projects such as BMBF, EU and Australian linkage grants, and new manufacturing methods, biotransformation and plant cell fermentation. Since 2022, Rima has been responsible for the global product management of lipids at Evonik’s Health Care business line. Rima’s academic background is in pharmaceutical chemical engineering. She obtained her Ph.D. from the university of Jena in Germany, where she specialized in optimizing processes for biodegradable polymers including for manufacturing and formulation. Rima is the author of several research papers and patent applications.

Dr. Philipp Schreppel

Philipp is currently Senior Director Business Development at Ethris where he is responsible for outlicensing of Ethris' programs and technology platform, fundraising and IR. He was previously advising private equity investors in the healthcare and life science space in Germany with a focus on commercial due diligence and value creation. Philipp has an Ms in pharmacy, Phd in Medicinal Chemistry from the University of Vienna and a Bs in Business Administration from the Vienna University of Economics and Business.